Methods: The percentage of p53V+, CD44v5+, CD44v6+, cerbB-2+, nm23+ cells and DNA content in the tumor tissue from 32 patients with carcinoma of endometrium were measured and analyzed by flow cytometry.
Objective To observe the different expression of S100A4, S100A8, S100A11 mRNA in carcinoma of endometrium, finding for the relationship between the S100A4, S100A8, S100A11 and the carcinoma of endometrium.
The patient developed two consecutive vaginal tumors diagnosed as metastases of the previously diagnosed endometrial carcinoma.
To assess survival, disease-specific survival, acute and late toxicity and quality of life in patients with curable endometrial carcinoma treated with adjuvant or primary radiotherapy at the age ≥ 75 years.
Expression and significance of Smad4 and p21WAF1 in endometrial carcinoma
Objective: To investigate the expression of Smad4 and p21WAF1 in endometrial carcinoma and its clinical significance.
Methods: Immunohistochemical method was used to detect Smad4 and p21WAF1 expression in 56 cases of endometrial carcinoma.
None of the 19 endometrial neoplasms after tamoxifen therapy was of the endometrioid type: 11 were mucinous adenocarcinomas, 4 clear cell carcinomas, 2 serous-papillary carcinomas, one carcinosarcoma and one malignant Müllerian mixed tumor.
The failure of demonstrating a steroid receptor complement in endometrial neoplasms was, in general terms, an adverse prognostic sign.
Furthermore, many endometrial neoplasms are originated from the luminal and glandular surface epithelium.